
- Pharmaceutical Commerce - January/February 2009
Cegedim Dendrite Tailors Software for Medical Science Liaisons
The key opinion leader/MSL relationship is the target
By partnering with the customer relationship-management firm Skila (Morris Plains, NJ) Cegedim Dendrite has created a solution set for medical science liaisons (MSLs), to be called Mobile Intelligence Medical & KOL Management. “The solution addresses a practice that is fragmented,” says Drew Bustos, a senior director at Cegedim Dendrite. “A lot of companies are using disparate systems rather than one cohesive solution based on their medical teams and the needs of their key customers.”
The solution will allow medical directors and MSLs to perform their daily activities through a central point, with access to meeting preparation tools, interaction management capabilities, and real-time outcomes reporting, according Cegedim Dendrite. Cross-organization information sharing, a centralized scientific repository, and compliance with regulatory guidelines are additional features.
Bustos says that product management collaborated with life sciences companies for 18 months to understand the MSL job function. “This tool is specifically for the MSLs,” he says. “A lot of their work is performed manually, and some of the tools they use are as basic as Microsoft Excel.” PC
Articles in this issue
over 16 years ago
Closing The Circle On Patient Adherenceover 16 years ago
3PLs Rise in Forward-Thinking Supply Chain Modelsover 16 years ago
A Pitched Battle in Cardiovascular Drug Marketingover 16 years ago
Wyeth Loses Supreme Court Case Over 'Implied' Pre-Emptionover 16 years ago
Syringe Design Gets a Makeoverover 16 years ago
Refinements in Cold Chain Secondary Packagingover 16 years ago
Inmar Rebrands Reverse-Logistics and Related Business Unitsover 16 years ago
The Packaging Contribution to Patient Adherenceover 16 years ago
Moving the Dial on Patient AdherenceNewsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.